Phase 1Active, not recruitingINTERVENTIONAL
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
ClinicalTrials.gov · NCT07299084 · Registry updated: 2026-05-19
- Condition / research focus
- Diabetes Mellitus, Type 2; Overweight; Obesity
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- Singapore
- Registry dates and results
- Start: 2026-01-14. Completion: 2026-11 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Tirzepatide (drug) — also listed as: LY3298176
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Singapore, Singapore